Novartis tests copy of Amgen's Enbrel in late-stage trial

LONDON (Reuters) - Sandoz, the generics unit of Novartis, has launched a late-stage trial with its biosimilar version of Amgen's Enbrel, consolidating its leading position in developing cheaper copies of complex biotech drugs.

Source: Reuters: Health - June 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news